These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 15812154

  • 1. Chemoprevention of gastric cancer: role of COX-2 inhibitors and other agents.
    Nardone G, Rocco A.
    Dig Dis; 2004; 22(4):320-6. PubMed ID: 15812154
    [Abstract] [Full Text] [Related]

  • 2. The selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model.
    Nam KT, Hahm KB, Oh SY, Yeo M, Han SU, Ahn B, Kim YB, Kang JS, Jang DD, Yang KH, Kim DY.
    Clin Cancer Res; 2004 Dec 01; 10(23):8105-13. PubMed ID: 15585646
    [Abstract] [Full Text] [Related]

  • 3. Use of NSAIDs for the chemoprevention of colorectal cancer.
    Herendeen JM, Lindley C.
    Ann Pharmacother; 2003 Nov 01; 37(11):1664-74. PubMed ID: 14565811
    [Abstract] [Full Text] [Related]

  • 4. Helicobacter pylori infection and the use of NSAIDs.
    Bazzoli F, De Luca L, Graham DY.
    Best Pract Res Clin Gastroenterol; 2001 Oct 01; 15(5):775-85. PubMed ID: 11566040
    [Abstract] [Full Text] [Related]

  • 5. Cyclooxygenase-2: from arthritis treatment to new indications for the prevention and treatment of cancer.
    Yamamoto DS, Viale PH.
    Clin J Oncol Nurs; 2003 Oct 01; 7(1):21-9. PubMed ID: 12629931
    [Abstract] [Full Text] [Related]

  • 6. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.
    Kismet K, Akay MT, Abbasoglu O, Ercan A.
    Cancer Detect Prev; 2004 Oct 01; 28(2):127-42. PubMed ID: 15068837
    [Abstract] [Full Text] [Related]

  • 7. Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs.
    Shaheen NJ, Straus WL, Sandler RS.
    Cancer; 2002 Feb 15; 94(4):950-63. PubMed ID: 11920463
    [Abstract] [Full Text] [Related]

  • 8. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention.
    Kashfi K, Rigas B.
    Biochem Pharmacol; 2005 Oct 01; 70(7):969-86. PubMed ID: 15949789
    [Abstract] [Full Text] [Related]

  • 9. An introduction to aspirin, NSAids, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part II.
    Moyad MA.
    Semin Urol Oncol; 2001 Nov 01; 19(4):306-16. PubMed ID: 11769882
    [Abstract] [Full Text] [Related]

  • 10. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
    Moyad MA.
    Semin Urol Oncol; 2001 Nov 01; 19(4):294-305. PubMed ID: 11769881
    [Abstract] [Full Text] [Related]

  • 11. [Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios].
    Limmer S, Ittel TH, Wietholtz H.
    Z Gastroenterol; 2003 Aug 01; 41(8):719-28. PubMed ID: 12910426
    [Abstract] [Full Text] [Related]

  • 12. Effect of Helicobacter pylori eradication on cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS) expression during gastric adaptation to aspirin (ASA) in humans.
    Fischer H, Huber V, Boknik P, Luess H, Neumann J, Schmitz W, Domschke W, Konturek JW.
    Microsc Res Tech; 2001 Jun 01; 53(5):336-42. PubMed ID: 11376494
    [Abstract] [Full Text] [Related]

  • 13. [Are COX-2 inhibitors truly able to prevent NSAIDs-associated ulcer?].
    Nishida T, Tsujii M, Tsuji S.
    Nihon Rinsho; 2004 Mar 01; 62(3):561-5. PubMed ID: 15038104
    [Abstract] [Full Text] [Related]

  • 14. Higher gastric cycloxygenase-2 expression and precancerous change in Helicobacter pylori-infected relatives of gastric cancer patients.
    Sheu BS, Yang HB, Sheu SM, Huang AH, Wu JJ.
    Clin Cancer Res; 2003 Nov 01; 9(14):5245-51. PubMed ID: 14614005
    [Abstract] [Full Text] [Related]

  • 15. COX-2, NSAIDs and human neoplasia. Part I: Colorectal neoplasms.
    Nasir A, Fernandez PM, Chughtai OR, Kaiser HE.
    In Vivo; 2002 Nov 01; 16(6):501-9. PubMed ID: 12494894
    [Abstract] [Full Text] [Related]

  • 16. The interaction of H. pylori infection and NSAIDs in cyclooxygenase-2 mRNA expression in gastric antral, corpus mucosa, and gastric ulcer.
    Wu CY, Wu MS, Chen CJ, Li MC, Lin JT, Chen GH.
    J Clin Gastroenterol; 2005 Jan 01; 39(1):50-5. PubMed ID: 15599211
    [Abstract] [Full Text] [Related]

  • 17. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection.
    McCarthy CJ, Crofford LJ, Greenson J, Scheiman JM.
    Am J Gastroenterol; 1999 May 01; 94(5):1218-23. PubMed ID: 10235197
    [Abstract] [Full Text] [Related]

  • 18. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.
    Gupta RA, Dubois RN.
    Nat Rev Cancer; 2001 Oct 01; 1(1):11-21. PubMed ID: 11900248
    [Abstract] [Full Text] [Related]

  • 19. Cyclooxygenase-2 inhibition prevents colorectal cancer: from the bench to the bed side.
    Samoha S, Arber N.
    Oncology; 2005 Oct 01; 69 Suppl 1():33-7. PubMed ID: 16210875
    [Abstract] [Full Text] [Related]

  • 20. Clinical pharmacology of selective COX-2 inhibitors.
    Capone ML, Tacconelli S, Sciulli MG, Patrignani P.
    Int J Immunopathol Pharmacol; 2003 Oct 01; 16(2 Suppl):49-58. PubMed ID: 14552704
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.